Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYAGhassan K. Abou-Alfa,Stephen Lam Chan,Masatoshi Kudo,George Lau,Robin Kate Kelley,Junji Furuse,Wattana Sukeepaisarnjaroen,Yoon-Koo Kang,Tu V. Dao,Enrico N. De Toni,Lorenza Rimassa,Valeriy Vladimirovich Breder,Alexander Vasilyev,Alexandra Heurgue,Vincent Tam,Kabir Mody,Satheesh Chiradoni Thungappa,Philip He,Alejandra Negro,Bruno SangroJOURNAL OF CLINICAL ONCOLOGY（2022）引用 232|浏览15暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
